Company Description

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.

Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.

The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.

ImageneBio, Inc. is headquartered in San Diego, California.

ImageneBio, Inc.

Country	United States
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	17
CEO	Kristin Yarema

Contact Details

Address: 12526 High Bluff Drive, Suite 345 San Diego, California 92130 United States
Phone	858 345 6265
Website	inmagenebio.com

Stock Details

Ticker Symbol	IMA
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001835579
CUSIP Number	45175G207
ISIN Number	US45175G2075
Employer ID	81-1697316
SIC Code	2836

Key Executives

Name	Position
Dr. Kristin Yarema Ph.D.	Chief Executive Officer and Director
Yanina Grant-Huerta	Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Kurinji Pandiyan Ph.D.	Chief Strategy and Operations Officer
Renuka Sivendran Ph.D.	Chief Technical Officer
Matt Robbins	General Counsel
Dr. Benjamin Porter-Brown M.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Aug 6, 2026	EFFECT	Notice of Effectiveness
Aug 5, 2026	S-8	Securities to be offered to employees in employee benefit plans
Aug 5, 2026	S-3	Registration statement under Securities Act of 1933
Aug 5, 2026	POS AM	Post-Effective amendments for registration statement
Aug 5, 2026	424B3	Prospectus
Aug 5, 2026	S-3	Registration statement under Securities Act of 1933
Aug 5, 2026	10-Q	Quarterly Report
Aug 5, 2026	8-K	Current Report
Jul 23, 2026	424B3	Prospectus
Jul 23, 2026	8-K	Current Report

View All SEC Filings